Novo Nordisk (NYSE:NVO) trimmed its full-year 2025 sales and profit forecast on Wednesday, citing weaker-than-expected U.S.

First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

GLP-1 weight loss drugs cause a slew of skin issues, including laxity, discoloration and pronounced fine lines. Now, doctors, ...

Obesity drugmaker Novo Nordisk on Wednesday cut its full-year sales and profit outlook amid lacklustre U.S. prescription data ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Andy Richter said he looked into taking weight-loss drugs despite not having type 2 diabetes. However, his insurance company ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on more ...